<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374881</url>
  </required_header>
  <id_info>
    <org_study_id>BL-3010</org_study_id>
    <nct_id>NCT00374881</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Single-Center, 5 Way Cross-Over Study to Assess the Effect of Adding Oral Phenylephrine and Oral Sorbitol to Low Dose (1.5 mg) Plain Oral Morphine in Human Volunteers: Analgesia and Side Effect Assessment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLineRx, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLineRx, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of the combined oral adjuvants phenylephrine and sorbitol on oral low
      dose morphine analgesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the efficacy of the combined oral
      adjuvants phenylephrine and sorbitol on oral low dose morphine analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Morphine Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sorbitol Phenylephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorbitol high concentration+Phenylephrine+Morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorbitol low concentration+Phenylephrine+Morphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine low dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorbitol+Phenylephrine</intervention_name>
    <description>Sorbitol+Phenylephrine</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorbitol+Phenylephrine+Morphine</intervention_name>
    <description>Sorbitol+Phenylephrine+Morphine</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorbitol low concentration+Phenylephrine+Morphine</intervention_name>
    <description>Sorbitol low concentration+Phenylephrine+Morphine</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent

          -  Healthy male or female between 18 and 40 years of age, inclusive.

          -  Women have to test negative for pregnancy.

          -  Body weight within 15% of ideal body weight based on Metropolitan Life assurance
             tables.

          -  No concomitant medications (prescription, OTC, vitamins, dietary supplements) within 7
             days prior to administration of study medication and during the study period.

          -  Ability to adhere to the visit schedule and protocol requirements and be available to
             complete the study

          -  Ability to participate successfully in training sessions that will be arranged for the
             volunteers prior to the study day, during which they will acquire consistency in the
             tests to be performed.

          -  Ability to satisfy a medical examiner about fitness to participate in the study

        Exclusion Criteria:

          -  prior use of chronic opioids

          -  mental illness prior or present

          -  evidence of significant concomitant disease, including renal, hepatic, cardiovascular,
             pulmonary, endocrinological, hematopoietic, or gastrointestinal disease, a neoplasm or
             any other clinically significant medical disorder, which in the Investigator's
             judgment contraindicate administration of the study medications

          -  known allergy to any of the drugs used in this study

          -  history of drug or alcohol abuse

          -  significant abnormalities in screening physical exam

          -  administration of drugs that may potentially inhibit or induce liver cytochrome P450
             activity within 3 weeks prior to Day 0

          -  any acute medical situation (e.g. acute infection) within 48 hours of Day 0, which is
             considered of significance by the Principal Investigator

          -  unusual diet

          -  administration of experimental medications within the previous 12 weeks.

          -  inability to communicate well with the Investigator (i.e., language problem, poor
             mental development or impaired cerebral function)

          -  subjects who, in the judgment of the investigators, are likely to be non-compliant or
             uncooperative or unwilling to sign a consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehuda Ginosar, Bsc, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Hadassah Hebrew University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Center, Department of Anesthesiology</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah En Kerem Medical Centre</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2006</study_first_posted>
  <last_update_submitted>April 14, 2008</last_update_submitted>
  <last_update_submitted_qc>April 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>BioLineRx</name_title>
    <organization>BioLineRx</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Sorbitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

